INOVIQ's NEURO-NET Technology Makes Breakthrough in Alzheimer's Disease Detection

Key Highlights:

- INOVIQ's NEURO-NET™ technology isolates brain-derived exosomes for Alzheimer's diagnosis.

- Superior to other methods, NEURO-NET identifies Alzheimer's biomarkers in blood.

- Over 200 differentially expressed proteins in Alzheimer's patients detected.

- Independent study validates findings, identifying 47 unique proteins in Alzheimer's samples.

Back of today’s ASX announcement the share surged 14.16% to reach $ 0.645 at 3:30 PM AEST, 12th June 24. 

INOVIQ Limited (ASX: IIQ) has announced a significant breakthrough in the detection of Alzheimer's disease using their innovative NEURO-NET™ technology. The technology's ability to isolate brain-derived exosomes from blood samples offers a new avenue for diagnosing neurological conditions. This announcement comes as a pivotal moment for INOVIQ, reinforcing their position at the forefront of diagnostic innovation.

Exosomes, small vesicles secreted by brain cells, provide crucial insights into the health and disease status of their parent cells. These exosomes can cross the blood-brain barrier, making them ideal candidates for diagnosing neurological diseases. INOVIQ's NEURO-NET technology captures these exosomes more effectively than any other commercially available methods.

Initial validation studies have shown promising results. Exosomes isolated using NEURO-NET contain proteins typically expressed by brain cells, and the technology has successfully identified known Alzheimer's biomarkers that were undetectable by other methods. An extensive analysis revealed over 200 proteins that are differentially expressed in Alzheimer's patients compared to healthy individuals.

Further validation came from a larger independent study conducted by the Walter & Elisa Hall Institute. This study, involving 48 Alzheimer's cases and 44 controls, confirmed the differential expression of previously identified proteins. Notably, 47 proteins were uniquely expressed in exosomes from Alzheimer's blood samples, providing robust discrimination between cases and controls.

INOVIQ's CEO, Leearne Hinch, emphasized the importance of NEURO-NET in expanding their exosome technology portfolio. She highlighted the potential for collaborations with pharmaceutical companies, diagnostic firms, and leading academic institutions to develop and validate new diagnostic tests for brain cancer, neuropsychiatric disorders, and neurodegenerative diseases.

Source: $IIQ ASX Announcement. 

Chairman David Williams underscored the significance of brain-derived exosomes in diagnosing and treating neurological diseases. The success of NEURO-NET not only enhances INOVIQ's diagnostic capabilities but also opens up new therapeutic possibilities for conditions like Alzheimer's and Parkinson's.

Source: $IIQ ASX Announcement. 

INOVIQ Limited continues to push the boundaries of biotechnology, with a focus on next-generation diagnostics and therapeutics for cancer. The company has already commercialized its EXO-NET exosome isolation technology for biomarker discovery and diagnostics development and is advancing clinical-stage diagnostics for ovarian and breast cancers, as well as early-stage exosome therapeutics for solid tumors.

This latest development with NEURO-NET reaffirms INOVIQ's commitment to leveraging cutting-edge technology to improve health outcomes. By isolating and analyzing brain-derived exosomes, INOVIQ is paving the way for more accurate and early detection of debilitating neurological diseases, offering hope for better management and treatment strategies in the future.